Fundraising FoxOptimvia
Cincinnati, US · Founded 2016 · Ohio LLC
Find your way into Optimvia
Sign up to see every warm intro you have to Optimvia
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Optimvia team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Optimvia engineers proteins to create new therapeutic products, focusing on designing enzymes and enzyme systems for biosynthetic manufacturing of critical medicines like heparin. The company uses its proprietary ADEPT Platform to computationally design novel proteins for pharmaceutical applications.
Founders & leadership
JT
John T. GlassChairman of the Board of Managers, Treasurer and Secretary
TF
Tarsis FerreiraManager and Chief Scientific Officer
Board
MK
Mickey KowitzBoard director
SG
Steve GeisBoard director
JR
James RothmanBoard director
JE
James E. Rothman, PhD
SG
Steve Geis, PhD MDBoard director
Reported raises · per SEC filings
Form D private placements$598.2K disclosed across 2 of 4 rounds · 2017–2026
▶$75KraisedApr 2026 · 2 investors · Other Health CareRule 506(b)
▶$75KraisedApr 2026 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Keith KleemanDirector, Executive Officer
- Steve GeisDirector
- Mickey KowitzDirector
- James RothmanDirector
- Offering amount
- $500K
- Amount sold
- $75K
- First sale
- Mar 2026
- Incorporated
- Limited Liability Company, Ohio
- Federal exemptions
- 06b
▶$523.2KraisedAug 2024 · 8 investors · Other Health CareRule 506(b)
▶$523.2KraisedAug 2024 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mickey KowitzDirector
- Keith M. KleemanDirector, Executive Officer
- Steve GeisDirector
- James RothmanDirector
- Offering amount
- $5M
- Amount sold
- $523.2K
- First sale
- Aug 2023
- Incorporated
- Limited Liability Company, Ohio
- Federal exemptions
- 06b
▶$5MofferedJan 2021 · Other Health CareRule 506(b)
▶$5MofferedJan 2021 · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Steve GeisDirector
- Mickey KowitzDirector
- James RothmanDirector
- Tarsis FerreiraExecutive Officer
- John GlassPromoter
- Keith M. KleemanExecutive Officer, Director
- Offering amount
- $5M
- Minimum investment
- $25K
- Proceeds to insiders
- $125K
- Incorporated
- Limited Liability Company, Ohio, 2017
- Federal exemptions
- 06b
▶$2.4MofferedMay 2017 · BiotechnologyRule 506(b)
▶$2.4MofferedMay 2017 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John T. GlassExecutive Officer, Director, Promoter
- Tarsis FerreiraExecutive Officer, Director, Promoter
- Keith M. KleemanExecutive Officer, Director, Promoter
- Offering amount
- $2.4M
- Minimum investment
- $25K
- Incorporated
- Limited Liability Company, Ohio, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Attovia TherapeuticsAttovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options. Its team includes a leadership team, board of directors, and scientific advisors experienced in drug development and company building.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies working in the same space as Optimvia.
Frequently asked questions
- What does Optimvia do?
- Optimvia engineers proteins to create new therapeutic products, focusing on designing enzymes and enzyme systems for biosynthetic manufacturing of critical medicines like heparin. The company uses its proprietary ADEPT Platform to computationally design novel proteins for pharmaceutical applications.
- How much funding has Optimvia raised?
- Optimvia has disclosed $598.2K raised across 2 of its 4 known rounds.
- Where is Optimvia headquartered?
- Optimvia is headquartered in Cincinnati, US.